- Home
- SPRB
as 12-18-2024 4:00pm EST
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 22.8M | IPO Year: | 2020 |
| Target Price: | $2.17 | AVG Volume (30 days): | 870.1K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.37 - $5.95 | Next Earning Date: | 11-11-2024 |
| Revenue: | $7,101,000 | Revenue Growth: | -1.40% |
| Revenue Growth (this year): | -50.01% | Revenue Growth (next year): | -67.64% |
Latest Spruce Biosciences Inc. News
SPRB Breaking Stock News: Dive into SPRB Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
MT Newswires
7 days ago
JMP Securities Downgrades Spruce Biosciences to Market Perform From Market Outperform
Benzinga
7 days ago
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
Business Wire
8 days ago
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Simply Wall St.
a month ago
Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
TipRanks
a month ago
Spruce Biosciences Reports Q3 2024 Earnings and Updates
Zacks
a month ago
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates
Business Wire
a month ago
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Compare SPRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRB Spruce Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.